OncoSec Appoints Robert Ward to its Board of Directors
Seasoned Biopharmaceutical Industry Leader Brings Extensive Experience in Drug Development and Commercialization SAN DIEGO and PENNINGTON, N.J., Nov. 8, 2018 -- (Healthcare Sales & Marketing Network) -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: O... Biopharmaceuticals, Oncology, Personnel OncoSec Medical, intratumoral cancer immunotherapies, TAVO (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2018 Category: Pharmaceuticals Source Type: news

Mr. Matthew Dallas and Mr. Jeffrey Young Appointed to Biostage Board of Directors
HOLLISTON, Mass., Nov. 8, 2018 -- (Healthcare Sales & Marketing Network) -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today an... Devices, Regenerative Medicine, Personnel Biostage, bioengineered organ implant, Cellframe (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2018 Category: Pharmaceuticals Source Type: news

Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors
Sharp to Bring Additional Financial Expertise to Sutro's Board SAN FRANCISCO, Nov. 8, 2018 -- (Healthcare Sales & Marketing Network) -- Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that Shalini Sharp, Chief Financial Officer and Executive Vice... Biopharmaceuticals, Oncology, Personnel Sutro Biopharma, XpressCF+ (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2018 Category: Pharmaceuticals Source Type: news

HemoScreen(TM) Hematology Analyzer for Point of Care, Receives FDA 510(k) Clearance
PixCell Medical's Point Of Care (POC) blood analyzer is the first cartridge-based system to be FDA cleared, providing all 20 CBC parameters. The HemoScreen™ should enable physicians to make more rapid and accurate decisions YOKNEAM, Israel, Nov. 7, 2... Devices, Diagnostics, FDA PixCell Medical, HemoScreen, blood analyzer, Lab On a Cartridge (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 7, 2018 Category: Pharmaceuticals Source Type: news

Ms. Ting Li Appointed to Biostage Board of Directors
HOLLISTON, Mass., Nov. 7, 2018 -- (Healthcare Sales & Marketing Network) -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus, and trachea, today a... Regenerative Medicine, Personnel Biostage, bioengineered organ implant, Cellframe (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 7, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Ortho Clinical Diagnostics VITROS(R) Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator for use on the VITROS(R) 5600 Integrated System
Expanded use on the VITROS® 5600 Integrated System will help Labs Maximize Workflow Efficiencies RARITAN, N.J., Nov. 6, 2018 -- (Healthcare Sales & Marketing Network) -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced... Diagnostics, HIV/AIDS, FDA Ortho Clinical Diagnostics, VITROS, HIV Combo Reagent Pack (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 6, 2018 Category: Pharmaceuticals Source Type: news

Cumberland Pharmaceuticals To Acquire VIBATIV(R)
FDA approved injectable anti-infective with life-saving potential NASHVILLE, Tenn., Nov. 6, 2018 -- (Healthcare Sales & Marketing Network) -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it has entered into a definitive agreement... Biopharmaceuticals, Acquisitions Cumberland Pharmaceuticals, Theravance Biopharma, VIBATIV, telavancin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 6, 2018 Category: Pharmaceuticals Source Type: news

Biostage awarded $1.1 million Phase II NIH SBIR Fast-Track grant to develop Cellspan(TM) Esophageal Implant (CEI) as a novel treatment for pediatric esophageal atresia
These nondilutive funds support development, testing and IND submission of the Company's pediatric esophageal implant candidate HOLLISTON, Mass., Nov. 6­­­, 2018 -- (Healthcare Sales & Marketing Network) -- Biostage, Inc. (OTCQB: BSTG), a b... Regenerative Medicine Biostage, Cellspan, Esophageal Implant, Cellframe, esophageal atresia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 6, 2018 Category: Pharmaceuticals Source Type: news

Lannett Announces Expanded Agreement With Strategic Alliance Partner, HEC Pharm Group, To Distribute Two FDA-Approved Products
Company Has Commenced Launch of Clarithromycin and Expects to Begin Marketing Entacapone In Early Calendar Year 2019 PHILADELPHIA, Nov. 6, 2018 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that it has e... Biopharmaceuticals, Licensing, Distribution Lannett Company, Sunshine Lake, HEC Pharm Group, clarithromycin, entacapone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 6, 2018 Category: Pharmaceuticals Source Type: news

AandD Medical Partners with HRS to Deliver Advanced Biometric Monitoring to Telehealth Patients
HOBOKEN, N.J., Nov. 6, 2018 -- (Healthcare Sales & Marketing Network) -- A&D Medical has partnered with Health Recovery Solutions (HRS) to bring the most cutting edge biometric monitoring equipment to patients using the HRS platform. A&D Medical has been ... Devices, Monitoring A&D Medical, Health Recovery Solutions, telehealth, biometric monitoring (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 6, 2018 Category: Pharmaceuticals Source Type: news

Galderma Announces FDA Approval of Restylane(R) Lyft For Midface Injection via Cannula
First and Only Hyaluronic Acid Dermal Filler for Cheeks with Cannula1 Now Offers Aesthetic Professionals New Delivery Method of Injectable Treatment FORT WORTH, Texas, Nov. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Galderma Laboratories, L.P... Devices, Dermatology, FDA Galderma Laboratories, Restylane, Restylane Lyft, dermal filler (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 5, 2018 Category: Pharmaceuticals Source Type: news

Biocept Announces New Executive Hires to its Sales and Marketing Organization
Appoints Scott Nicholson as Vice President of National Sales - US; Cory Dunn as Vice President of Marketing SAN DIEGO, Nov. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biops... Diagnostics, Oncology, Personnel Biocept, liquid biopsy, Target Selector, progesterone receptor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 5, 2018 Category: Pharmaceuticals Source Type: news

CMS Grants Outpatient Pass-through Payment to the remedand#275;(R) System for the Treatment of Central Sleep Apnea
Pass-through Payment to Provide Additional Medicare Reimbursement for the remedē System MINNETONKA, Minn., Nov. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Respicardia, Inc. announced today that the Centers for Medicare and Medicaid Servi... Devices, Neurology, Reimbursement Respicardia, remedē System, phrenic nerve stimulation, sleep apnea (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 5, 2018 Category: Pharmaceuticals Source Type: news

Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman
Louis G. Lange, M.D., Ph.D. appointed as Lead Independent Director SAN FRANCISCO, Nov. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing in... Biopharmaceuticals, Personnel Audentes Therapeutics, Myotubular Myopathy, Crigler-Najjar syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 5, 2018 Category: Pharmaceuticals Source Type: news

Shoulder Innovations Announces FDA 510(k) Clearance For Shoulder Technology
HOLLAND, Mich., Nov. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Shoulder Innovations announced today that they have received FDA clearance for their InSet Humeral Short Stem System. This is a key addition to their expanding shoulder portfolio a... Devices, Orthopaedic, FDA Shoulder Innovations, InSet Humeral Short Stem, shoulder arthroplasty (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 5, 2018 Category: Pharmaceuticals Source Type: news

EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Application based on results of pivotal phase 3 QuANTUM-R study of quizartinib in patients with relapsed/refractory FLT3-ITD AML Quizartinib is the first FLT3 inhibitor to demonstrate a survival benefit in a randomized phase 3 study in patients with rel... Biopharmaceuticals, Oncology, Regulatory Daiichi Sankyo, quizartinib, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 5, 2018 Category: Pharmaceuticals Source Type: news

TempTraq(R) Wearable Temperature Monitoring Patch Earns CE Mark Approval
TempTraq® Wearable, Bluetooth Temperature Monitor Provides Peace of Mind for Parents and Home Care Givers, and Sets a New Standard of Care for Hospitals in Europe CLEVELAND, Nov. 2, 2018 -- (Healthcare Sales & Marketing Network) -- Blue Spark Techn... Devices, Monitoring, Regulatory Blue Spark Technologies, TempTraq, temperature monitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 2, 2018 Category: Pharmaceuticals Source Type: news

Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval for SYMPAZAN(TM) (clobazam) Oral Film
SYMPAZAN is the first and only FDA-approved oral film formulation of clobazam, a benzodiazepine approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older(1) SYMPAZAN is delivered via ... Biopharmaceuticals, Drug Delivery, FDA Aquestive Therapeutics, SYMPAZAN, clobazam, PharmFilm (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 2, 2018 Category: Pharmaceuticals Source Type: news

Torque Announces Appointment of Immunotherapy Pioneer F. Stephen Hodi, MD, to Scientific Advisory Board and Alex Bruni as COO/ CFO
CAMBRIDGE, Mass., Nov. 2, 2018 -- (Healthcare Sales & Marketing Network) -- Torque, an immuno-oncology company developing first-in-class Deep Primed™ T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced today the ap... Biopharmaceuticals, Oncology, Personnel Torque, Deep Primed T Cell, tumor microenvironment, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 2, 2018 Category: Pharmaceuticals Source Type: news

BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease
STOCKHOLM, Oct. 2, 2018 -- (Healthcare Sales & Marketing Network) -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a Notice of Option Exercise under the Research, Development, Option and License Agreement dat... Biopharmaceuticals, Neurology, Licensing BioArctic, AbbVie, alpha-synuclein, Parkinson's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 2, 2018 Category: Pharmaceuticals Source Type: news

FDA's Center for Devices and Radiological Health and Center for Drug Evaluation and Research on agency's warning to consumers about genetic tests that claim to predict patients' responses to specific medications
SILVER SPRING, Md., Nov. 1, 2018 -- (Healthcare Sales & Marketing Network) -- As a public health agency, one of our key roles is to promote and advance safe and effective medical product innovations. One rapidly advancing, and very promising, area of scie... Biopharmaceuticals, Diagnostics, FDA FDA, genetic testing, pharmacogenetic testing (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2018 Category: Pharmaceuticals Source Type: news

Cantel Appoints Bill Haydon to Senior Vice President and General Manager of Medical Division
LITTLE FALLS, N.J., Nov. 1, 2018 -- (Healthcare Sales & Marketing Network) -- CANTEL MEDICAL CORP. (NYSE: CMD) announced today that Bill Haydon has been recently appointed to Senior Vice President and General Manager of the Medical division. Mr. Haydon wi... Devices, Personnel CANTEL MEDICAL, medical device reprocessing, reprocessing (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2018 Category: Pharmaceuticals Source Type: news

OsteoRemedies(R) Announces the First FDA Cleared Dual-Antibiotic Spacer and Bone Cement with Gentamicin and Vancomycin
MEMPHIS, Tenn., Nov. 1, 2018 -- (Healthcare Sales & Marketing Network) -- OsteoRemedies®, LLC, a company focused on providing simple solutions to complex disorders, is pleased to announce the launch of the REMEDY SPECTRUM™️ GV Hip Spacer System... Devices, Orthopaedic, FDA OsteoRemedies, REMEDY SPECTRUM GV, Hip Spacer System, SPECTRUM GV, Bone Cement (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2018 Category: Pharmaceuticals Source Type: news

Chris Cargill Appointed Executive Vice President and Chief Financial Officer of Sosei
TOKYO and LONDON, November 1, 2018 -- (Healthcare Sales & Marketing Network) -- Sosei Group Corporation ("Sosei" or "the Company"; TSE Mothers Index: 4565), a world-leading GPCR medicine design and development company, has appointed Mr... Biopharmaceuticals, Personnel Sosei Group (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2018 Category: Pharmaceuticals Source Type: news

Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
TAIPEI, Taiwan and SAN DIEGO, Nov. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Senhwa Biosciences Inc. (TPEx: 6492) announced today that FDA has approved its IND application for basal cell carcinoma (BCC). To accelerate the development of this ne... Biopharmaceuticals, Oncology, FDA Senhwa Biosciences, Silmitasertib, basal cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2018 Category: Pharmaceuticals Source Type: news

AbbVie Receives European Commission Approval of VENCLYXTO(R) (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
The approval is based on the MURANO Phase 3 clinical trial, in which VENCLYXTO® plus rituximab reduced the risk of disease progression or death by 83 percent and overall survival was prolonged compared to bendamustine in combination with rituximab, a s... Biopharmaceuticals, Oncology, Regulatory AbbVie, VENCLYXTO, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2018 Category: Pharmaceuticals Source Type: news

1DROP Raises $4.25 Million to Develop Next-Generation Portable Medical Diagnostics
Investment will support commercialization and development of panels of new diagnostic tests BOSTON and NEUCHATEL, Switzerland, Oct. 31, 2018 -- (Healthcare Sales & Marketing Network) -- 1DROP, a life science company developing and commercializing an ea... Diagnostics, Venture Capital 1DROP (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 31, 2018 Category: Pharmaceuticals Source Type: news

Shavit Capital Completes $100 Million Investment Round for Its Fifth Fund
Shavit is one of the leading funds in Israel specializing in pre-IPO investments JERUSALEM, October 31, 2018 -- (Healthcare Sales & Marketing Network) -- Shavit Capital announces the completion of a $100 million funding round for its fifth fund. Founde... Biopharmaceuticals, Devices, Venture Capital Shavit Capital (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 31, 2018 Category: Pharmaceuticals Source Type: news

Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products
Anticipates projected pro forma annual net revenue of between $80 and $90 million Company expects to reduce senior debt by $34 million Company files for voluntary pre-arranged plan of reorganization with support of majority in dollar amount of debt h... Biopharmaceuticals, Acquisitions Egalet, Iroko Pharmaceuticals, SoluMatrix, VIVLODEX, TIVORBEX, ZORVOLEX, INDOCIN (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 31, 2018 Category: Pharmaceuticals Source Type: news

G3 Pharmaceuticals Signs Exclusive License and Option Agreement for Treating Diastolic Heart Failure (HFpEF) by Inhibiting Galectin-3
Galectin-3 inhibitors offer new hope for an important unmet medical need BURLINGTON, Mass., Oct. 30, 2018 -- (Healthcare Sales & Marketing Network) -- G3 Pharmaceuticals, a development-stage biopharmaceutical company located in Burlington, MA, today an... Biopharmaceuticals, Cardiology, Licensing G3 Pharmaceuticals, galectin-3, diastolic heart failure, heart failure (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 30, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves INVOKANA(R) (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
INVOKANA® is now the only oral diabetes treatment approved to reduce the risk of these cardiovascular events Approval aligns with ADA and AACE treatment guidance and supports use of INVOKANA® across a broad range of patients TITUSVILLE, N.J.,... Biopharmaceuticals, Endocrinology, Cardiology, FDA Janssen Pharmaceutical, INVOKANA, canagliflozin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 30, 2018 Category: Pharmaceuticals Source Type: news

cue-Rx(TM) Launch Revolutionizes At-Home Patient Medication Dispensing
Provides Improved Medication Adherence, Greater Independence for Seniors, and Real-Time Communication to Caregivers NEW HOPE, Pa., Oct. 29, 2018 -- (Healthcare Sales & Marketing Network) -- Solbright Group, Inc. (OTC: SBRT), soon to be renamed Iota Com... Devices, Product Launch Iota Communications, Solbright Group, cue-Rx (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 29, 2018 Category: Pharmaceuticals Source Type: news

Perrigo Confirms Patent Challenge For Generic Version Of Kerydin(R)
DUBLIN, Oct. 29, 2018 -- (Healthcare Sales & Marketing Network) -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Anacor Pharmaceuticals, Inc., initiated patent litigation on October 25, 2018 in the United States District Court for the Distri... Biopharmaceuticals, Generics, Litigation Perrigo, Anacor Pharmaceuticals, tavaborole, Kerydin, onychomycosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 29, 2018 Category: Pharmaceuticals Source Type: news

Australis Finalizes Definitive Agreement to Acquire Rthm Technologies Inc.
LAS VEGAS, Oct. 29, 2018 -- (Healthcare Sales & Marketing Network) - Australis Capital Inc. (CSE: AUSA) ("Australis" or the "Company") is pleased to announce that the Company has finalized the definitive agreement (the "Agreement&... Devices, Monitoring, Mergers & Acquisitions Rthm Technologies (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 29, 2018 Category: Pharmaceuticals Source Type: news

Millar Seeks to Advance Medical Devices with Wireless Pressure Monitoring
HOUSTON, Oct. 29, 2018 -- (Healthcare Sales & Marketing Network) -- Millar, Inc., medical device manufacturer and OEM solutions partner, is pleased to announce the availability of a wireless pressure platform for integration in medical device technology. ... Devices, Monitoring, Product Launch Millar, MEMS, pressure sensor, wireless pressure monitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 29, 2018 Category: Pharmaceuticals Source Type: news

OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
SAN DIEGO and NEW JERSEY, Oct. 29, 2018 -- (Healthcare Sales & Marketing Network) -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the appointment of Kellie Malloy Foerter ... Biopharmaceuticals, Oncology, Personnel OncoSec Medical, intratumoral immunotherapies, tavokinogene, telseplasmid (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 29, 2018 Category: Pharmaceuticals Source Type: news

Retrospective Study Featuring OSSDSIGN(R) Cranial Published in World Neurosurgery
UPPSALA, Sweden, Oct. 29, 2018 -- (Healthcare Sales & Marketing Network) -- OssDsign AB, the Swedish designer, manufacturer and distributor of regenerative implants for cranial and facial reconstruction, today announced positive results from a retrospecti... Devices, Regenerative Medicine, Neurosurgery OssDsign, OSSDSIGN Cranial, cranioplasty (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 29, 2018 Category: Pharmaceuticals Source Type: news

Pneuma Respiratory, Inc. Announces J. Knox Singleton Joins the Board of Directors
BOONE, N.C., Oct. 26, 2018 -- (Healthcare Sales & Marketing Network) -- Pneuma Respiratory, Inc., which has developed PNEUMAHALER™, the first breath-activated digital inhaler (BDI), announced its Board of Directors has elected shareholder J. Knox Singleto... Biopharmaceuticals, Drug Delivery, Personnel Pneuma Respiratory, PNEUMAHALER (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 26, 2018 Category: Pharmaceuticals Source Type: news

Perrigo Confirms Patent Challenge For Generic Version Of Narcan(R)
DUBLIN, Oct. 26, 2018 -- (Healthcare Sales & Marketing Network) -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Adapt Pharma Operations Limited, Adapt Pharma Inc., Adapt Pharma Ltd. and Opiant Pharmaceuticals initiated patent litigation on ... Biopharmaceuticals, Generics, Litigation Perrigo, Adapt Pharma, Narcan, naloxone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 26, 2018 Category: Pharmaceuticals Source Type: news

Tissue Analytics Announces Rafael Mazuz as New Independent Board Member
BALTIMORE, Oct. 26, 2018 -- (Healthcare Sales & Marketing Network) -- Tissue Analytics, Inc., the leading mobile imaging and artificial intelligence platform for wound, skin, and ostomy management, today announced the appointment of Rafael Mazuz to the co... Devices, Wound Care, Personnel Tissue Analytics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 26, 2018 Category: Pharmaceuticals Source Type: news

Mayne Pharma Acquires FDA-approved halobetasol foam, Complementing US Dermatology Portfolio
Mayne Pharma Group Limited ("Mayne Pharma") (ASX: MYX) has acquired the FDA approved halobetasol propionate foam 0.05% for an investment of up to US$32 million and an ongoing earn out payment Halobetasol foam is a highly complementary dermatol... Biopharmaceuticals, Acquisition, Dermatology Mayne Pharma, halobetasol foam, psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 26, 2018 Category: Pharmaceuticals Source Type: news

Abbott Introduces the Next Generation of Influenza A and B and Strep A Assays with Fastest-Ever Time to Molecular Results
NEW ASSAYS EMPOWER CLINICIANS TO MORE QUICKLY MAKE THE RIGHT DIAGNOSIS AT THE POINT-OF-CARE AND PRESCRIBE THE RIGHT TREATMENT ABBOTT PARK, Ill., Oct. 25, 2018 -- (Healthcare Sales & Marketing Network) -- Abbott (NYSE: ABT) announced today that the U.S.... Diagnostics, FDA, Product Launch Abbott, Influenza, Streptococcus, ID NOW (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2018 Category: Pharmaceuticals Source Type: news

FogPharma Appoints Dr. Barbara Weber to its Board of Directors
CEO of Tango Therapeutics and Venture Partner at Third Rock Ventures to lend her expertise to FogPharma as the Company continues to advance a powerful new class of medicines - cell-penetrating miniproteins - for the treatment of serious diseases BOSTON,... Biopharmaceuticals, Personnel FogPharma, miniprotein (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2018 Category: Pharmaceuticals Source Type: news

89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
Investment round led by founding investors, OrbiMed Israel and OrbiMed US, and Longitude Capital, with participation by RA Capital Management and Pontifax Company acquires NASH assets from Teva, initiates Phase 1 clinical trial Rohan Palekar, former ... Biopharmaceuticals, Venture Capital, Personnel 89Bio, nonalcoholic steatohepatitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2018 Category: Pharmaceuticals Source Type: news

EYLEA(R) (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
First trial in non-proliferative diabetic retinopathy to show both a reduction in vision-threatening complications and in development of diabetic macular edema Both every 8-week and every 16-week dosing groups met primary and key secondary endpoints at ... Biopharmaceuticals, Ophthalmology Regeneron Pharmaceuticals, EYLEA, aflibercept, diabetic retinopathy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2018 Category: Pharmaceuticals Source Type: news

Skyline Urology Acquires First ExactVu(TM) Micro-Ultrasound System in California for Real-Time Targeted Prostate Biopsies
ExactVu™ micro-ultrasound platform now available to provide real-time targeted biopsies for one of Southern California's largest private urology practices LOS ANGELES, Oct. 25, 2018 -- (Healthcare Sales & Marketing Network) - Exact Imaging (www.exact... Devices, Urology Exact Imaging, ExactVu, micro-ultrasound (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2018 Category: Pharmaceuticals Source Type: news

Mercaptor Announces the Appointment of World-Renowned Neuropathologist, Dr. Adriano Aguzzi to Scientific Advisory Board
NOVATO, Calif., Oct. 25, 2018 -- (Healthcare Sales & Marketing Network) -- Mercaptor Discoveries (Mercaptor), a company developing small molecules that target brain trauma and neurodegenerative diseases, announced today that Dr. Adriano Aguzzi, MD, PhD, i... Biopharmaceuticals, Neurology, Personnel Mercaptor Discoveries, Captons, neuroprotectant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves New SynchroMed(TM) II myPTM(TM) Personal Therapy Manager That Enables Patients to Alleviate Unpredictable Pain
myPTM Allows Patients to Personalize Their Treatment by Delivering On-Demand Boluses, or Drug Doses, Within Therapeutic Limits Set by Their Physician DUBLIN - October 24, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration ... Devices, Drug Delivery, Neurology, FDA Medtronic, SynchroMed II, myPTM, Personal Therapy Manager, pain pump (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 24, 2018 Category: Pharmaceuticals Source Type: news

Inova Diagnostics Launches First FDA Cleared Calprotectin Extraction Device
SAN DIEGO, Oct. 24, 2018 -- (Healthcare Sales & Marketing Network) -- Inova Diagnostics, a world leader in autoimmune disease diagnostic systems and reagents for the clinical laboratory, is proud to announce the clearance by the US Food and Drug Administr... Devices, Diagnostics, FDA, Product Launch Inova Diagnostics, QUANTA Flash, Calprotectin, inflammatory bowel disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 24, 2018 Category: Pharmaceuticals Source Type: news

Bausch and Lomb To Launch First-In-Class Surgical Support Applications For Stellaris Elite(TM) Vision Enhancement System On IBM Cloud
Watson IoT Services on the IBM Cloud Are Being used by Bausch & Lomb to Help Eye Surgeons Increase Efficiency, Cut Costs and Improve Workflow when using Stellaris Elite™ Vision Enhancement System LAVAL, Quebec and ARMONK, N.Y., Oct. 24, 2018 -- (Healthc... Devices, Ophthalmology, Surgery, Product Launch Bausch & Lomb, Bausch Health Companies, Stellaris Elite (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 24, 2018 Category: Pharmaceuticals Source Type: news